What's happened
The NHS will begin a gradual rollout of Mounjaro, a weight-loss drug, prioritizing patients with the highest clinical needs. Initially, fewer than 10% of eligible patients will have access, with a full rollout expected over 12 years. The decision aims to protect NHS services while addressing obesity.
Why it matters
What the papers say
According to The Guardian, the NHS's decision to limit initial access to Mounjaro is a response to concerns about overwhelming healthcare services, stating that 'the difficult decision to roll out Mounjaro slowly over 12 years was made in order to protect other vital NHS services.' Meanwhile, BBC News highlights that 'only those patients under the care of specialist weight-management services will be offered it initially,' indicating a cautious approach to implementation. The Independent emphasizes that 'Mounjaro is only for people who are medically obese and need medical help to reach a healthier weight,' reinforcing the drug's targeted use. This contrasts with some patient groups expressing disappointment over the slow rollout, as noted by BBC News, which states that 'patient groups have expressed disappointment at the decision to give the NHS so long.'
How we got here
Mounjaro, also known as tirzepatide, was approved for weight management in the UK in November 2023. The National Institute for Health and Care Excellence (NICE) has now recommended its use for patients with a BMI over 35 and at least one obesity-related health issue.
Common question
-
What Should Patients Know About the NHS Mounjaro Rollout?
The NHS is set to gradually roll out Mounjaro, a new weight-loss drug, prioritizing patients with the highest clinical needs. This phased approach raises many questions about eligibility, access, and the drug's effectiveness. Here’s what you need to know.
More on these topics
-
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Col. Eli Lilly, a
-
Nice is the seventh most populous urban area in France and the capital of the Alpes-Maritimes department. The metropolitan area of Nice extends beyond the administrative city limits, with a population of about 1 million on an area of 721 km².
-
The National Institute for Health and Care Excellence is an executive non-departmental public body of the Department of Health in England, which publishes guidelines in four areas: